Beneficial effects of metformin on glomerular podocytes in diabetes

Biochem Pharmacol. 2021 Oct:192:114687. doi: 10.1016/j.bcp.2021.114687. Epub 2021 Jul 16.

Abstract

Podocytes and their foot processes form an important cellular layer of the glomerular barrier involved in regulating glomerular permeability. Disturbances in podocyte function play a central role in the development of proteinuria in diabetic nephropathy. The retraction of podocyte foot processes forming a slit diaphragm is a common feature of proteinuria. Metformin is an oral antidiabetic agent of the biguanide class that is widely recommended for the treatment of high blood glucose in patients with type 2 diabetes mellitus. In addition to lowering glucose, several recent studies have reported potential beneficial effects of metformin on diabetic kidney function. Furthermore, a key molecule of the antidiabetic mechanism of action of metformin is adenosine 5'-monophospate-activated protein kinase (AMPK), as the metformin-induced activation of AMPK is well documented. The present review summarizes current knowledge on the protective effects of metformin against pathological changes in podocytes that are induced by hyperglycemia.

Keywords: AMP-activated protein kinase; Hyperglycemia; Insulin signaling; Metformin; Podocyte; Reactive oxygen species.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Animals
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / metabolism*
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / metabolism
  • Metformin / pharmacology
  • Metformin / therapeutic use*
  • Podocytes / drug effects
  • Podocytes / metabolism*
  • Treatment Outcome

Substances

  • Hypoglycemic Agents
  • Insulin
  • Metformin
  • AMP-Activated Protein Kinases